The findings contradict previous research suggesting high-risk patients with multiple myeloma were more likely to have a ...

A recent study published in Genes & Diseases reveals new insights into the relationship between immune cell characteristics, ...

BIIB begins phase III dosing of felzartamab primary membranous nephropathy study, targeting a tough-to-treat condition with ...

Biogen has commenced dosing in the Phase III PROMINENT trial, assessing the efficacy and safety of the felzartamab drug.

The Phase 3 study will evaluate the efficacy and safety of the investigational drug felzartamab compared to tacrolimus in adults diagnosed with primary membranous nephropathy (PMN). PROMINENT is ...

A recent study published in Genes & Diseases reveals new insights into the relationship between immune cell characteristics, blood metabolites, and ...

The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.

The good news, I guess, is that we have very many different treatment options for relapse refractory multiple myeloma, and some of that is considered in the background of what we do for patients with ...

Panelists discuss how quadruplet regimens show improved efficacy over triplet regimens without significantly increased safety ...

Number one is, given the high degree of efficacy that the CAR T cells have, there's a great interest in knowing should we really be waiting for giving these CAR T cells to patients with relapse and ...

Johnson & Johnson (J&J) has announced that its CD38-directed antibody Darzalex (daratumumab) has been recommended by the ...